PIQ.AX Sygnały na żywo | Maksymalizuj zyski z Getagraph.com

Live Chart Being Loaded With Signals

Commentary (3 geg. 2024 @ 08:52):

Stats
Dzisiejszy wolumen	131 789
Średni wolumen	280 492
Kapitalizacja rynkowa	137.44M
EPS	$0 ( 2024-02-25 )
Następna data zysków	( $0 ) 2024-07-21
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-21.00
ATR14	$0.00800 (0.76%)

Proteomics International Korelacja

10 Najbardziej pozytywne korelacje

10 Najbardziej negatywne korelacje

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

Proteomics International Finanse

Annual	2023
Przychody:	$730 340
Zysk brutto:	$-1.62M (-221.14 %)
EPS:	$-0.0535

FY	2023
Przychody:	$730 340
Zysk brutto:	$-1.62M (-221.14 %)
EPS:	$-0.0535

FY	2022
Przychody:	$1.49M
Zysk brutto:	$-568 619 (-38.18 %)
EPS:	$-0.0471

FY	2021
Przychody:	$1.31M
Zysk brutto:	$1.31M (100.00 %)
EPS:	$-0.0356

Financial Reports:

No articles found.

Proteomics International

Proteomics International Laboratories Limited operates as a medical technology company with a focus on the area of proteomics. It provides PromarkerD, a predictive test for diabetic kidney disease; and develops diagnostic tests for endometriosis and giardia. The company also offers analytical services, including specialist contract research. Proteomics International Laboratories Ltd has a research agreement with the Busselton Population Medical Research Institute and the Janssen Research & Development for the research of diabetic kidney disease treatment; and partnership with QIMR Berghofer Medical Research Institute for the detection of oesophageal adenocarcinoma. The company was founded in 2001 and is based in Perth, Australia.